Jacobio Pharma (1167.HK) has received IND (Investigational New Drug) approval of its self-developed drug JAB-26766 (PARP7 inhibitor) from the Center for Drug Evaluation (CDE) of China. Jacobio plans to initiate a Phase I/IIa advanced solid tumors clinical trial in the China.
PARP7 inhibitors target I/O (immuno-oncology) signaling pathway and can be used to treat various solid tumors such as squamous NSCLC, and HNSCC. Studies show that, PARP7 inhibitors have the potential to directly inhibit tumor growth and enhance the anti-tumor immune response. JAB-26766 is an orally administered small-molecule with significant antitumor activity against a variety of tumor models in mice.
PARP7 is located downstream of STING signaling pathway, and JAB-26766 has potential to combine with Jacobio
